Hewlett Packard mgmt. structure must allow independent review of device production records, FDA says.
This article was originally published in The Gray Sheet
Executive Summary
HEWLETT PACKARD ORGANIZATIONAL INADEQUACIES FOR GMP COMPLIANCE CITED BY FDA in an Oct. 10 warning letter to Hewlett Packard's Medical Products Group. During a Sept. 17 through Oct. 3 inspection of HP's Andover, Massachusetts facility, the agency noted the firm's "failure to have in place an adequate organizational structure and sufficient personnel to assure that the devices produced by Hewlett Packard are manufactured in accordance with the requirements" of good manufacturing practice regulations, the warning letter states.
You may also be interested in...
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.
US FDA’s Anti-Misinformation Campaigns Look Safer After Supreme Court Oral Arguments
FDA’s efforts to tackle misinformation may face fewer legal obstacles moving forward, following oral arguments at the Supreme Court on a case that could have broad ramifications for how the government communicates public health information.
The Dog That Didn’t Bark: ODAC Gives Nod To Three Products Despite Negative FDA Reviews
Oncologic Drugs Advisory Committee was swayed by views of its disease area experts in favorably reporting out Geron’s imetelstat for myelodysplastic syndromes and supplemental applications for the CAR-T products Carvykti and Abecma in earlier lines of multiple myeloma.